The FDA Just Approved a Long-Lasting Injection to Prevent HIV

US food And the drug administration has just approved Lenaakapavir, an injected form of it HIV Resistance which is about 100 percent effective and requires only two doses per year. Science The magazine describes the drug The most important scientific advance Of 2024.

In clinical trials, people weighing 35 kg over 35 kg were proven to be 99.9 percent effective in preventing HIV infection through sexual infections. The drug, an antheretroviral, does not stimulate the resistance reaction, but blocks HIV from its early reproduction – especially, disrupts the effectiveness of the virus’s capsid protein. This happens so long as the body receives injection every six months.

Lenakapavi has already been approved as the treatment of viruses as the treatment of HIV in some countries that have been approved among resistant people against other treatment. However, before this week, its profilactic use has not been approved anywhere, the FDA’s decision has made a new development in the fight against HIV/AIDS epidemic.

The drug is not the first drug that can be taken printedly for protection against HIV infection: Pre-XPosa prophylaxis (prep) pills are already available in many countries, including the United States. But they must be taken every day, and ensures the running access to these drugs, and people actually think of accepting them, A familiar challengeThe It is hoped that the long -lasting effects of Lenakapavir will make people easier to be protected against the virus.

According to its creator, Lenakapavir will be marketed under Yaztugo. The company is committed to producing 10 million doses by 2026.

“This is a historic tihasik day for decades against HIV. Yaztugo offers a true opportunity to end our time and a true opportunity to help end the HIV epidemic,” said Daniel Od, president and chief executive of Gilliad, A. Statement Wednesday.

However, the price of Lenakapavir can be a hindrance to access. The annual list of YegTugo will be in the United States, every person in the United States, $ 28,218. Winnie Bilanima, Executive Director of Joint UN Program related to HIV/AIDS (UNAIDS) Flag in the past The drug that is unnecessary for many African people, where the drug is most likely to affect. Roughly two-thirds Sub-Saharan lives in Africa among people living in HIV worldwide.

Giliad says a Statements last year That it has developed Lenaakapavir “a wide range of global, sustainable access to enable”, though the company has not yet provided detailed information about how it will do. An alternative may be “voluntary licensing”, where other companies are allowed to produce and sell the generic version of the patent product exclusively for people in specific (short-income) countries. Liverpool University researchers Has been calculated That one year worth $ 25 can be provided as $ 25.

This story was originally attended Wired In Spanish And have been translated from Spanish.